Cargando…
Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors
There is an urgent need for vaccines and antiviral drugs to combat the COVID-19 pandemic. Encouraging progress has been made in developing antivirals targeting SARS-CoV-2, the etiological agent of COVID-19. Among the drug targets being investigated, the viral main protease (M(pro)) is one of the mos...
Autores principales: | Ma, Chunlong, Hu, Yanmei, Townsend, Julia Alma, Lagarias, Panagiotis I., Marty, Michael Thomas, Kolocouris, Antonios, Wang, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523112/ https://www.ncbi.nlm.nih.gov/pubmed/32995786 http://dx.doi.org/10.1101/2020.09.15.299164 |
Ejemplares similares
-
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib,
and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease
Inhibitors
por: Ma, Chunlong, et al.
Publicado: (2020) -
Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M(pro) and cathepsin L
por: Sacco, Michael Dominic, et al.
Publicado: (2020) -
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L
por: Sacco, Michael Dominic, et al.
Publicado: (2020) -
Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System
por: May, Holly C., et al.
Publicado: (2018) -
Synergistic Inhibition of SARS-CoV-2 Replication
Using Disulfiram/Ebselen and
Remdesivir
por: Chen, Ting, et al.
Publicado: (2021)